Korean Journal of Pharmacognosy (생약학회지)

The Korean Society of Pharmacognosy (한국생약학회)
권호 표지

Effect of Cnidii Rhizoma on Proliferation of Breast Cancer Cell, Nitric Oxide Production and Ornithine Decarboxylase Activity

천궁이 유방암세포 증식, Nitric Oxide 생성 및 Ornithine Decarboxylase 활성에 미치는 영향

  • Nam, Kyung-Soo (Intractable Diseases Research Center and Department of Pharmacology, College of Medicine, Dongguk University) ;
  • Son, Ok-Lye (Intractable Diseases Research Center and Department of Pharmacology, College of Medicine, Dongguk University) ;
  • Lee, Kyung-Hwa (Intractable Diseases Research Center and Department of Pharmacology, College of Medicine, Dongguk University) ;
  • Cho, Hyun-Jung (Intractable Diseases Research Center and Department of Pharmacology, College of Medicine, Dongguk University) ;
  • Shon, Yun-Hee (Intractable Diseases Research Center and Department of Pharmacology, College of Medicine, Dongguk University)
  • 남경수 (동국대학교 난치병한양방치료연구센터 및 의과대학 약리학교실) ;
  • 손옥례 (동국대학교 난치병한양방치료연구센터 및 의과대학 약리학교실) ;
  • 이경화 (동국대학교 난치병한양방치료연구센터 및 의과대학 약리학교실) ;
  • 조현정 (동국대학교 난치병한양방치료연구센터 및 의과대학 약리학교실) ;
  • 손윤희 (동국대학교 난치병한양방치료연구센터 및 의과대학 약리학교실)
  • Published : 2004.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

The effect of water extract from Cnidii Rhizoma (CRW) on proliferation of human breast cancer cells, nitric oxide production, nitric oxide synthase expression, and ornithine decarboxylase activity was tested. CRW inhibited the growth of both estrogen-dependent MCF-7 and estrogen-independent MDA-MB-23I human breast cancer cells. Lipopolysaccharide-induced nitric oxide (NO) production was significantly reduced by CRW at the concentration of 0.5, 1.0 and 5.0 mg/ml. Expression of inducible nitric oxide synthase (iNOS) was also suppressed with the treatment of CRW in Raw 264.7 cells. CRW inhibited induction of ornithine decarboxylase by 12-0-tetradecanoylphorbol-13-acetate, a key enzyme of polyamine biosynthesis, which is enhanced in tumour promotion. Therefore, CRW is worth further investigation with respect to breast cancer chemoprevention or therapy.

Keywords

References

  1. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K, Kavanah, M., Cronin, W. M., Voge~, V, Robidoux, A., Dirnitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., Wolmark, N., and other National Surgical Adjuvant Breast and Bowel Project Investigators (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J. Natl. Cancer Inst. 18: 1371-1388
  2. Kroncke, K. D., Fehsel, K., Suschek, C., and Kolb-Bachofen, V. (2001) Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. Int. Immunopharmacol. 1: 1407-1420 https://doi.org/10.1016/S1567-5769(01)00087-X
  3. Tamir, S. and Tannenbaum, S. R. (1996) The role of nitric oxide(NO) in the carcinogenic process. Biochim. Biophys. Acta 1288: F31-F36
  4. Ambs, S., Hussain, S. P., and Harris, C. C. (1997) Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J. 11: 443-448
  5. Felley-Bosco, E. (1998) Role of nitric oxide in genotoxicity: implication for carcinogenesis. Cancer Metastasis Rev. 17: 25-37 https://doi.org/10.1023/A:1005948420548
  6. Knowles, R. G. and Moncada, S. (1994) Nitric oxide synthases in mammals. Biochem. J. 298: 249-258
  7. Li, L., Carol, T., and Susan, K. G. (2000) Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverse spontaneous tumors in ODClRas transgenic mice. Cancer Res. 60: 5696-5730
  8. Huber, M. and Poulin, R. (1996) Permissive role of polyamines in the cooperative action of estrogens and insulin or insulin-like growth factor I on human breast cancer cell growth. J. Clin. Endocrinol. Metab. 81: 113-123 https://doi.org/10.1210/jc.81.1.113
  9. 李尙仁(1998) 本草學, 407-409, 修書院, 서울
  10. Macchiarini, P., Fontanini, G., Hardin, M. J., Squartini, F., and Angeletti, C. A. (1992) Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 340: 145-146 https://doi.org/10.1016/0140-6736(92)93217-B
  11. Wink, D. A., Hanbauer, I., Grisham, M. B., Laval, F., Nims, R. W., Laval, J., Cook, J., Pacelli, R., Liebmann, I., Krishna, M., Ford, P. C., and Mitchell, J. B. (1996) Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Curro Top. Cell Regul. 34: 159-187 https://doi.org/10.1016/S0070-2137(96)80006-9
  12. Ambs, S., Bennett, W. P., Merriam, W. G., Ogunfusika, M. 0., Oser, S. M., Harrington, A. M., Shields, P. G., FelleyBosco, E., Hussain, S. P., and Harris, C. C. (1999) Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl. Cancer Inst. 91: 86-88 https://doi.org/10.1093/jnci/91.1.86
  13. Vakkala, M., Kahlos, K., Lakari, E., Paakko, P., Kinnula, V., and Soini, Y. (2000) Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in situ and invasive breast carcinomas. Clin. Cancer Res. 6: 2408-2416
  14. Robbins, R. A., Barnes, P. J., Springall, D. R., Warren, J. B., Kwon, O. J., Buttery, L. D., Wilson, A. J., Geller, D. A., and Polak, J. M. (1994) Expression of inducible nitric oxide in human lung epithelial cells. Biochem. Biophys. Res. Comm. 203: 209-218 https://doi.org/10.1006/bbrc.1994.2169
  15. Thomsen, L. L., Miles, D. W., Happerfield, L., Bobrow, L. G., Knowles, R. G., and Moncada, S. (1995) Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 72: 41-44 https://doi.org/10.1038/bjc.1995.274
  16. Tschugguel, W., Knogler, W., Czerwenka, K., Mildner, M., Weninger, W., Zeillinger, R., and Huber, J. C. (1996) Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. Br. J. Cancer 74: 1423-1426 https://doi.org/10.1002/1097-0142(19940815)74:4+<1423::AID-CNCR2820741605>3.0.CO;2-G
  17. Manni, A., Astrow, S. H., Gammon, S., Thompson, J., Mauger, D., and Washington, S. (2001) Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res. Treat. 67: 147-156 https://doi.org/10.1023/A:1010697218986
  18. Glikman, P., Vegh, I., Pollina, M. A., Mosto, A. H., and Levy, C. M. (1987) Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer (Phila) 60: 2237-2243 https://doi.org/10.1002/1097-0142(19871101)60:9<2237::AID-CNCR2820600923>3.0.CO;2-J
  19. Suh, N., Glasebrook, A. L., Palkowitz, A. D., Bryant, H. U., Burris, L. L., Starling, J. J., Pearce, H. L., Williams, C., Peer, C., Wang, Y., and Sporn, M. B. (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 61: 8412-8415
  20. Marton, L. J. and Pegg, A. E. (1995) Polyarnines as targets for therapeutic intervention. Annu. Rev. PhamUlcol. Toxicol. 35: 55-91 https://doi.org/10.1146/annurev.pa.35.040195.000415
  21. Green, J. E., Shibata, M. A., Shibata, E., Moon, R. C., Anver, M. R., Kelloff, G., and Lubet, R. (2001) 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 TIt-antigen transgenic mice. Cancer Res. 61: 7449-7455